Business Wire | Dec 20, 2021 08:00AM EST

AtriCure to Participate in the 40th Annual J.P. Morgan Healthcare Conference

Dec. 20, 2021

MASON, Ohio--(BUSINESS WIRE)--Dec. 20, 2021--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming 40th Annual J.P. Morgan Healthcare Conference.

AtriCure's management is scheduled to present on Monday, January 10, 2022, at 7:30 a.m. Eastern Time. Interested parties may access a live audio webcast of the presentation by visiting the "Investors" section of the company's website at https://ir.atricure.com.

About AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure's Isolator(r) Synergy(tm) Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure's AtriClip(r) Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure's Hybrid AF(tm) Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure's cryoICE cryoSPHERE(r) probe is cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211220005112/en/

CONTACT: Angie Wirick AtriCure, Inc. Chief Financial Officer (513) 755-5334 awirick@atricure.com

CONTACT: Lynn Lewis Gilmartin Group Investor Relations (415) 937-5402 lynn@gilmartinir.com